BRPI1013893A2 - uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. - Google Patents

uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry.

Info

Publication number
BRPI1013893A2
BRPI1013893A2 BRPI1013893A BRPI1013893A BRPI1013893A2 BR PI1013893 A2 BRPI1013893 A2 BR PI1013893A2 BR PI1013893 A BRPI1013893 A BR PI1013893A BR PI1013893 A BRPI1013893 A BR PI1013893A BR PI1013893 A2 BRPI1013893 A2 BR PI1013893A2
Authority
BR
Brazil
Prior art keywords
tetrahydrobiopterin
marker
therapeutic agent
fabry disease
fabry
Prior art date
Application number
BRPI1013893A
Other languages
English (en)
Inventor
David F Moore
Erland Arning
Raphael Schiffmann
Teodoro G Bottiglieri
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of BRPI1013893A2 publication Critical patent/BRPI1013893A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI1013893A 2009-04-09 2010-04-09 uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. BRPI1013893A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16815009P 2009-04-09 2009-04-09
US12/757,420 US8410101B2 (en) 2009-04-09 2010-04-09 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
PCT/US2010/030552 WO2010118330A2 (en) 2009-04-09 2010-04-09 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease

Publications (1)

Publication Number Publication Date
BRPI1013893A2 true BRPI1013893A2 (pt) 2016-04-05

Family

ID=42934560

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013893A BRPI1013893A2 (pt) 2009-04-09 2010-04-09 uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry.

Country Status (10)

Country Link
US (1) US8410101B2 (pt)
EP (1) EP2416776A4 (pt)
JP (1) JP5463410B2 (pt)
KR (1) KR20120022849A (pt)
CN (1) CN102387803A (pt)
AU (1) AU2010233147B2 (pt)
BR (1) BRPI1013893A2 (pt)
CA (1) CA2756272A1 (pt)
MX (1) MX2011010565A (pt)
WO (1) WO2010118330A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
WO2013055954A1 (en) 2011-10-11 2013-04-18 The Regents Of The University Of California Biomarker for abdominal aortic aneurysm
KR101913199B1 (ko) * 2016-03-18 2018-10-31 울산대학교 산학협력단 파브리병 진단용 바이오마커 및 이의 용도
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
WO2020023922A1 (en) 2018-07-27 2020-01-30 The Regents Of The University Of California Biomarker for thoracic aortic aneurysm
CN114814063A (zh) * 2022-04-08 2022-07-29 宁波熙宁检测技术有限公司 一种检测人体内四氢生物蝶呤的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
JP4251485B2 (ja) * 2003-08-20 2009-04-08 生化学工業株式会社 糖脂質の測定法、疾病検出方法及びキット
CA2543315A1 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US7297810B2 (en) 2004-12-30 2007-11-20 3M Innovative Properties Company High refractive index monomers for optical applications
KR100759716B1 (ko) 2006-09-26 2007-10-04 고려대학교 산학협력단 복합기능 자성체 코어 - 반도체 쉘 나노 입자 및 그의제조방법
US20100144008A1 (en) * 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
US20100047844A1 (en) * 2006-12-21 2010-02-25 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnostic marker for fabry disease

Also Published As

Publication number Publication date
AU2010233147A1 (en) 2011-10-13
CA2756272A1 (en) 2010-10-14
JP2012523570A (ja) 2012-10-04
WO2010118330A2 (en) 2010-10-14
US8410101B2 (en) 2013-04-02
MX2011010565A (es) 2011-10-19
US20100260747A1 (en) 2010-10-14
WO2010118330A3 (en) 2011-03-31
KR20120022849A (ko) 2012-03-12
CN102387803A (zh) 2012-03-21
AU2010233147B2 (en) 2012-10-25
EP2416776A4 (en) 2012-09-26
JP5463410B2 (ja) 2014-04-09
EP2416776A2 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
PT2641596T (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
BRPI0907036A2 (pt) Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BR112013014934A2 (pt) um leito de via férrea de poliuretano, um método de preparação e o uso do mesmo
ZA201209145B (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BRPI0819630A2 (pt) Montagem de interface de paciente para terapia respiratória
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
IL216876A (en) Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BRPI0921802A8 (pt) uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
BRPI0817198A2 (pt) (ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI0917026A2 (pt) uso de sucralose como agente granulador
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
BRPI1011412A2 (pt) composição para liberação sustentada de droga compreendendo alutinante geopolimérico
BR112015012443A2 (pt) composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
PT2525796T (pt) Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]